Relación entre niveles plasmáticos de efavirenz y alteraciones lipémicas / Efavirenz plasma levels and dyslipidemia
O.F.I.L
; 31(1): 64-69, 2021. graf, tab
Article
in Es
| IBECS
| ID: ibc-221804
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
RESUMEN
El objetivo del presente trabajo es evaluar si existe relación entre los niveles plasmáticos de efavirenz y la aparición de dislipemia como hipercolesterolemia, hipretrigliceridemia o aumento de LDL-c.Se realizaron niveles plasmáticos de efavirenz a los pacientes en tratamiento con este fármaco desde septiembre de 2012 hasta junio de 2015. Se registraron los parámetros lipídicos correspondientes a cada analítica. Las determinaciones de efavirenz se realizaron mediante cromatografía líquida de alta eficacia. Los datos se manejaron mediante el programa Quick Statistics Calculator y Excel 2007.Los niveles plasmáticos de efavirenz superiores a 4.000 ng/ml se asocian en nuestro estudio con una mayor frecuencia de niveles de colesterol superiores a 200 mg/dl.Este estudio puede ser de utilidad para aquellas zonas en las que usen pautas de tratamiento con este fármaco de manera frecuente. (AU)
ABSTRACT
The aim of this study is to evaluate if there is a relationship between plasma levels of efavirenz and the occurrence of dyslipidemia such as hypercholesterolemia, hypretrigiceridemia or increased LDL-c.Plasma levels of efavirenz were performed to patients under treatment with this drug during the period from September 2012 to June 2015. Lipid parameters corresponding to each analytical were recorded. Determinations of efavirenz were analyzed by high performance liquid chromatography. Data were managed using the Quick Statistics Calculator and Excel 2007 program.Plasma levels of efavirenz higher than 4,000 ng/ml were associated, in our study, with a higher frequency of cholesterol levels higher than 200 mg/dl.This study may be useful to those areas where treatment guidelines with this drug are used on a frequent basis. (AU)
Key words
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Pharmaceutical Preparations
/
Chromatography
/
34628
/
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
/
Hyperlipidemias
Limits:
Humans
Language:
Es
Journal:
O.F.I.L
Year:
2021
Document type:
Article